Table 1.
Selected ongoing clinical trials exploring adenosine pathway.
| Molecular Target | Agents | Phase | Indications | Clinical Trial Identifier | Status |
|---|---|---|---|---|---|
| CD73 | Oleclumab + Durvalumab |
II | Renal, pancreatic, head and neck and NSCLC with DNA Methylation | NCT04262375 | Active not recruiting |
| CD73 | Oleclumab +/− Durvalumab |
I | Bladder cancer | NCT03773666 | Recruiting |
| CD73 | Carbo-taxol + Durvalumab +/− Oleclumab |
I/II | Triple negative breast cancer (TNBC) | NCT03616886 | Recruiting |
| CD73 | Oleclumab + Durvalumab vs. Durvalumab + Monalizumab |
II | NSCLC | NCT03822351 | Recruiting |
| CD39 | TTX-030 + Pebrolizumab or Chemotherapy |
I | Solid tumors | NCT03884556 | Recruiting |
|
CD73
Anti-A2AR |
Oleclumab + AZD4635 + Osimertinib |
I/II | NSCLC | NCT03381274 | Recruiting |
|
CD73
Anti-A2AR |
Oleclumab + AZD4635 + Durvalumab |
II | Prostate cancer | NCT04089553 | Recruiting |
|
CD39
CD73 |
IPH5201 + Oleclumab +/− Durvalumab |
I | Solid tumors | NCT04261075 | Recruiting |